Patrick J. Loehrer

Last updated
Patrick J. Loehrer
Born1952 (age 70–71)
Alma mater
Scientific career
Institutions
Indiana University School of Medicine
Website cancer.iu.edu/research-trials/member-bio.php?id=3029

Patrick J. Loehrer is an American oncologist who is Indiana University Distinguished Professor, Joseph W. and Jackie J. Cusick Professor in Oncology, Professor of medicine, Indiana University School of Medicine; Director emeritus, Indiana University Melvin and Bren Simon Comprehensive Cancer Center. [1]

Contents

Career

Along with Lawrence Einhorn, Kenneth Pennington, Rafat Ansari, Prasad Mantravadi, and William B. Fisher, in 1984, he co-founded the Hoosier Oncology Group. [2]

In 2002, he became Director of the Division of Hematology/Oncology at Indiana University School of Medicine. [3]

Loehrer was director of the Indiana University Melvin and Bren Simon Comprehensive Cancer Center from 2010-2021. He succeeded Steve Williams who was the founding director of the NCI designated center at the time of its designation in 1999. As Director, Loehrer worked to build the NCI designated cancer center, ultimately leading to NCI designation as a Comprehensive Cancer Center in 2019. [4] He was director until January 2021 when he was succeeded by Kelvin Lee. [5] Loehrer is a member of the Experimental and Developmental Therapeutics Program at the IU Simon Comprehensive Cancer Center.

He founded the Academic Model Providing Access to Healthcare (AMPATH)-Oncology Program, a partnership of North American institutions with Moi University and Moi Teaching and Referral Hospital in Kenya. [6]

More recently, he has hosted the Oncology, Etc., an American Society of Clinical Oncology podcast, with David Johnson. [7]

Research

Loehrer has made notable contributions to research in the care of patients with colorectal cancer, [8] germ cell tumor, [9] pancreatic cancer, [10] bladder cancer, [11] and thymic epithelial tumors. [12]

Awards and honors

Related Research Articles

Lawrence Einhorn is an American oncologist at Indiana University School of Medicine. A pioneer in cancer treatment research, Einhorn developed cisplatin-based chemotherapy regimens that increased cure rates while minimizing toxic side effects.

Nicholas J. Vogelzang was a medical oncologist with Comprehensive Cancer Centers of Nevada (CCCN). He serves as Medical Director of the Research Executive Committee and Associate Chair of the Developmental Therapeutics and Genitourinary Committees for US Oncology Research. His research interests include clinical trials for genitourinary malignancies and mesothelioma.

The Intergroup Rhabdomyosarcoma Study Group (IRS) was a U.S. and Canadian clinical trial cooperative group created with the mission of studying childhood cancers. In 2000, IRS merged with several other pediatric cooperative groups to form the Children's Oncology Group (COG). This merger has seen its fair share of problems, especially with regard to integrating the various databases associated with each individual cooperative group. One such initiative to consolidate these databases involves caBIG, or cancer BIG, which is guided and supported by the National Cancer Institute (NCI) in Bethesda, Maryland. They published a report on cancer treatment protocols published by the National Institute of Health in 2001, and a separate report in 2011 on improving outcomes for patients with low-risk embryonal rhabdomyosarcoma.

<span class="mw-page-title-main">Transitional cell carcinoma</span> Medical condition

Transitional cell carcinoma, also called urothelial carcinoma, is a type of cancer that typically occurs in the urinary system. It is the most common type of bladder cancer and cancer of the ureter, urethra, and urachus. It accounts for 95% of bladder cancer cases.

<span class="mw-page-title-main">Cediranib</span> Chemical compound

Cediranib is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases.

Harry F. Bisel, M.D. (1918–1994) was an American oncologist. With Fred Ansfield, Herman Freckman, Arnoldus Goudsmit, Robert Talley, William Wilson, and Jane Wright, was one of the founding members of the American Society of Clinical Oncology (ASCO). This group of pioneering doctors, through the formation of ASCO, is largely credited with the development of modern American clinical oncology. In 1964, Bisel was elected the first president of ASCO. He was active in the American Cancer Society and was a consultant to the National Cancer Institute. Bisel was a founding member of the American Society of Preventive Oncology as well as the American Association for Cancer Education.

The American Society of Clinical Oncology (ASCO) is a professional organization representing physicians of all oncology sub-specialties who care for people with cancer. Founded in 1964 by Fred Ansfield, Harry Bisel, Herman Freckman, Arnoldus Goudsmit, Robert Talley, William Wilson, and Jane C. Wright, it has nearly 45,000 members worldwide.

Geriatric oncology is a branch of medicine that is concerned with the diagnosis and treatment of cancer in the elderly, usually defined as aged 65 and older. This fairly young but increasingly important subspecialty incorporates the special needs of the elderly into the treatment of cancer.

<span class="mw-page-title-main">Hydrazine sulfate</span> Chemical compound

Hydrazine sulfate, more properly hydrazinium hydrogensulfate, is a salt of the cation hydrazinium and the anion bisulfate (hydrogensulfate), with the formula N2H6SO4 or more properly [N2H5]+[HSO4]−. It is a white, water-soluble solid at room temperature.

James L. Gulley is an American cancer researcher and the Director of the Medical Oncology Service at National Cancer Institute.

Treatment of lung cancer refers to the use of medical therapies, such as surgery, radiation, chemotherapy, immunotherapy, percutaneous ablation, and palliative care, alone or in combination, in an attempt to cure or lessen the adverse impact of malignant neoplasms originating in lung tissue.

<span class="mw-page-title-main">Sandra M. Swain</span> American oncologist

Sandra M. Swain is an American oncologist, breast cancer specialist and clinical translational researcher. She is currently a professor of Medicine at the Georgetown University School of Medicine and the Associate Dean for Research Development at Georgetown University Medical Center (GUMC) and MedStar Health as well as an adjunct professor of Medicine at the F. Edward Hébert School of Medicine of the Uniformed Services University of Health Sciences. She is also a past President of the American Society of Clinical Oncology (ASCO), serving from 2012 through 2013.

<span class="mw-page-title-main">University of Michigan Rogel Cancer Center</span>

The University of Michigan Rogel Cancer Center is a cancer research and treatment institution based in Ann Arbor, Michigan, United States. The Rogel Cancer Center is affiliated with the University of Michigan and Michigan Medicine.

EPI-7386 is an N-terminal domain antiandrogen, or antagonist of the N-terminal domain (NTD) of the androgen receptor (AR), which is under development for the treatment of prostate cancer. The compound was developed as a successor of previous drugs in the EPI series such as EPI-001, ralaniten (EPI-002), and ralaniten acetate (EPI-506). EPI-7386 shows 20-fold higher antiandrogenic potency than ralaniten in vitro (IC50 = 535 nM vs. 9,580 nM, respectively), as well as greater stability in human hepatocytes. It is planned to enter phase I clinical trials in 2020.

Roy S. Herbst is an American oncologist who is the Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, and Associate Director for Translational Research at Yale Cancer Center and Yale School of Medicine in New Haven, Connecticut.

Stephanie J. Lee is an American haematologist and physician scientist who is Professor and Associate Director at the Fred Hutchinson Cancer Research Center. Lee works to improve the lives of blood stem cell transplant and bone marrow patients by better understanding the chronic form of graft-versus-host disease. Lee is the former President of the American Society of Hematology.

Maura Lianne Gillison is an American medical oncologist and molecular epidemiologist. She is credited as the first investigator to establish a connection between HPV and oral cancer.

Christopher Hourigan is a physician-scientist known for work on measurable residual disease in acute myeloid leukemia.

<span class="mw-page-title-main">Defactinib</span> Pharmaceutical

Defactinib is an inhibitor of PTK2, also known as focal adhesion kinase (FAK), Pyk2, and MELK which was developed by Pfizer and licensed to Verastem Oncology as a potential treatment for solid tumors.

Eve Wiltshaw was a British physician who was a researcher and consultant at the Royal Marsden Hospital. She was an expert in medical oncology, and led the United Kingdom's first clinical trials of cisplatin. In 1998, she wrote A History of the Royal Marsden Hospital.

References

  1. ↑ "Patrick J. Loehrer". The Cancer Letter. Retrieved 22 June 2022.
  2. ↑ "Our Story". Hoosier Cancer Research Network.
  3. ↑ "Patrick J. Loehrer: University Honors and Awards: Indiana University". University Honors & Awards.
  4. ↑ "Indiana University Simon Cancer Center becomes 51st NCI-designated comprehensive cancer center". The Cancer Letter. 6 August 2019.
  5. ↑ "Indiana University Melvin and Bren Simon Comprehensive Cancer Center becomes 51st NCI-designated comprehensive cancer center". The Cancer Letter. 6 August 2019.
  6. ↑ November 25, ASCO. "ASCO President-Elect Candidates Discuss Key Issues in Oncology - The ASCO Post". ascopost.com.
  7. ↑ "ASCO". education.asco.org.
  8. ↑ Saltz, Leonard B.; Meropol, Neal J.; Loehrer, Patrick J.; Needle, Michael N.; Kopit, Justin; Mayer, Robert J. (1 April 2004). "Phase II Trial of Cetuximab in Patients With Refractory Colorectal Cancer That Expresses the Epidermal Growth Factor Receptor". Journal of Clinical Oncology. 22 (7): 1201–1208. doi: 10.1200/JCO.2004.10.182 . ISSN   0732-183X. PMID   14993230.
  9. ↑ Williams, Stephen D.; Birch, Robert; Einhorn, Lawrence H.; Irwin, Linda; Greco, F. Anthony; Loehrer, Patrick J. (4 June 1987). "Treatment of Disseminated Germ-Cell Tumors with Cisplatin, Bleomycin, and either Vinblastine or Etoposide". New England Journal of Medicine. 316 (23): 1435–1440. doi:10.1056/NEJM198706043162302. ISSN   0028-4793. PMID   2437455.
  10. ↑ Loehrer, Patrick J.; Feng, Yang; Cardenes, Higinia; Wagner, Lynne; Brell, Joanna M.; Cella, David; Flynn, Patrick; Ramanathan, Ramesh K.; Crane, Christopher H.; Alberts, Steven R.; Benson, Al B. (1 November 2011). "Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial". Journal of Clinical Oncology. 29 (31): 4105–4112. doi:10.1200/JCO.2011.34.8904. ISSN   0732-183X. PMC   3525836 . PMID   21969502.
  11. ↑ Loehrer, P. J.; Einhorn, L. H.; Elson, P. J.; Crawford, E. D.; Kuebler, P.; Tannock, I.; Raghavan, D.; Stuart-Harris, R.; Sarosdy, M. F.; Lowe, B. A. (July 1992). "A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study". Journal of Clinical Oncology. 10 (7): 1066–1073. doi:10.1200/JCO.1992.10.7.1066. ISSN   0732-183X. PMID   1607913.
  12. ↑ Loehrer, P J; Kim, K; Aisner, S C; Livingston, R; Einhorn, L H; Johnson, D; Blum, R (1 June 1994). "Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. The Eastern Cooperative Oncology Group, Southwest Oncology Group, and Southeastern Cancer Study Group". Journal of Clinical Oncology. 12 (6): 1164–1168. doi:10.1200/JCO.1994.12.6.1164. ISSN   0732-183X. PMID   8201378.
  13. ↑ "Loehrer and IU Simon Comprehensive Cancer Center honored during Summit". Big Ten Cancer Research Consortium. 8 January 2021.
  14. ↑ "The ASCO Post". ascopost.com.
  15. ↑ "Patrick Loehrer". College of Engineering - Purdue University.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.